Herein, our in vitro results demonstrated that a low concentration of nintedanib (1 μM) can promote STAT3 phosphorylation and downstream protein expression (PD-L1 and β2M) in different tumor cell lines (A549, MC38 and LLC) and gradually suppress these pathways at high doses (5 μM). Here, STAT3 is linked to neoplasm.